Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma Equity Group ASOCSE:PEG +3.29% Debt-to-Equity is 0.42 as of Jun. 2026, which is 40% above its 10-year median of 0.30. The stock has 3 warning signs investors should review. Among 956 Biotechnology companies, Pharma Equity Group AS ranks worse than 71.34% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Pharma Equity Group AS's Debt-to-Equity or its related term are showing as below:
OCSE:PEG'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.3 Max: 1.69
Current: 0.42
During the past 13 years, the highest Debt-to-Equity Ratio of Pharma Equity Group AS was 1.69. The lowest was 0.00. And the median was 0.30.
OCSE:PEG's Debt-to-Equity is ranked worse than 71.34% of 956
companies
in the Biotechnology industry
Industry Median: 0.16
vs OCSE:PEG: 0.42
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Pharma Equity Group AS Debt-to-Equity Related Terms
Pharma Equity Group AS Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Pharma Equity Group AS's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:PEG vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Pharma Equity Group AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Equity Group AS Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Pharma Equity Group AS's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Equity Group AS (OCSE:PEG) has a Debt-to-Equity of 0.42 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Pharma Equity Group AS and its competitors. This is 40% above median its historical median of 0.30. According to the industry distribution chart, Pharma Equity Group AS ranks #682 out of 956 companies in the Biotechnology industry, placing it in the top 71.3%.
Is Pharma Equity Group AS's Debt-to-Equity too high?
Pharma Equity Group AS's current Debt-to-Equity of 0.42 is 40% above median its 10-year median of 0.30. The Biotechnology industry median Debt-to-Equity is 0.16. Pharma Equity Group AS's value of 0.42 is 162.5% above this industry median. Based on the distribution chart, Pharma Equity Group AS ranks #682 out of 956 companies in the Biotechnology industry, which is below the industry midpoint.
How does Pharma Equity Group AS's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Equity Group AS ranks #682 out of 956 companies for Debt-to-Equity. This places Pharma Equity Group AS in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Pharma Equity Group AS's value of 0.42 is 162.5% above this benchmark. While the company's 10-year median is 0.30 vs. the industry median of 0.16, Pharma Equity Group AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Equity Group AS's current Debt-to-Equity of 0.42 is 162.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Pharma Equity Group AS and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Equity Group AS's current Debt-to-Equity is 0.42, which is 40% above median its own 10-year median of 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current Debt-to-Equity of 0.42. The current Debt-to-Equity is 0.42, which is 40% above median its 10-year median of 0.30 and 162.5% above the Biotechnology industry median of 0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current Debt-to-Equity is 0.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:PEG has been successfully added to your 
